Clinical Trials Directory

Trials / Unknown

UnknownNCT03140033

Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery

Sublingual Misoprostol Versus Placebo to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized Controlled Study

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
158 (estimated)
Sponsor
Ain Shams Maternity Hospital · Academic / Other
Sex
Female
Age
19 Years – 35 Years
Healthy volunteers
Accepted

Summary

Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized Controlled Trial

Detailed description

This study aims to evaluate efficacy and safety of subligual misoprostol in reducing blood loss during cesarean section , a randomized double blinded prospective controlled trial conducted at Ain Shams maternity hospital . 158 women who fulfilled the inclusion criteria enrolled in this study .the patients randomized into two groups one of them will receive sublingual misoprostol 400 micrograms ( misotac )and the other will receive placebo( Ranitak ),all patients will subjected to history,physical examination,and investigations.preparation of patients (preload and antibiotics )according to hospital protocol.All C.S will be perfomed using spinal anaesthesia ,pfannenstiel incision of the skin ,open of abdomen in layers ,at cord clamping the patients will receive the medication sublingual and 20IU of oxytocin intravenous infusion simultaneous by the anesthesiologist,then close in anatomical layers.blood loss during C.S will be calculated following placental delivery to the end of surgery,and from the end of the operation to 6h after birth.the need for additional uterotonics agents,blood transfusion and adverse effects of the study drug will be recorded.

Conditions

Interventions

TypeNameDescription
DRUGMisoprostol Oral Tabletat cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
DRUGRanitidine Oral Tabletat cord clamping the patient will recieve ranitidine sublingually

Timeline

Start date
2016-07-01
Primary completion
2017-05-01
Completion
2017-05-01
First posted
2017-05-04
Last updated
2017-05-04

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03140033. Inclusion in this directory is not an endorsement.